1	Directional anchor genes refine polygenic informed treatment selection in
2	schizophrenia and bipolar disorder
3	
4	William R. Reay ^{1,2} , Michael P. Geaghan ³ , Joshua R. Atkins ¹ , Vaughan J. Carr ^{4,5,6} , Melissa J.
5	Green ^{4,5} , Murray J. Cairns ^{1,2 *}
6	
7	¹ School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan,
8	NSW, Australia
9	² Centre for Brain and Mental Health Research, Hunter Medical Research Institute,
10	Newcastle, NSW, Australia
11	³ Kinghorn Centre for Clinical Genomics, Garvan Medical Research Institute, Darlinghurst,
12	NSW, Australia
13	⁴ School of Psychiatry, University of New South Wales, Randwick, NSW, Australia
14	⁵ Neuroscience Research Australia, Sydney, NSW, Australia
15	⁶ Department of Psychiatry, Monash University, Melbourne, VIC, Australia
16	
17	To whom correspondence should be addressed: Professor Murray Cairns
18	(Murray.Cairns@newcastle.edu.au)
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

34 ABSTRACT

35 Genetically informed drug development and repurposing is an attractive prospect for 36 improving outcomes in patients with psychiatric illness; however, the effectiveness of these endeavours can be confounded by heterogeneity. In this study, we propose a novel approach 37 38 that links interventions implicated by disorder-associated genetic risk, at the population level, to a framework that can target these compounds to individuals. Specifically, results from 39 40 genome-wide association studies are integrated with expression data to prioritise individual "directional anchor" genes for which the predicted risk-increasing direction of expression 41 42 could be counteracted by an existing drug. While these compounds represent plausible 43 therapeutic candidates, they are not likely to be equally efficacious for all individuals. To 44 account for this heterogeneity, we constructed polygenic scores restricted to variants annotated 45 to the network of genes that interact with each directional anchor gene. These metrics, we call pharmagenic enrichment scores (PES), identify individuals with a higher burden of genetic 46 47 risk, localised in biological processes related to the candidate drug target, to inform precision 48 drug repurposing. We used this approach to investigate schizophrenia and bipolar disorder and 49 reveal several compounds targeting specific directional anchor genes that could be plausibly repurposed, including antioxidants, vitamins, antiarrhythmics, and lipid modifying agents. 50 51 These genetic risk scores, mapped to the networks associated with target genes, revealed 52 biological insights that cannot be observed in undifferentiated genome-wide polygenic risk 53 score (PRS). For example, an enrichment of these partitioned scores in schizophrenia cases with otherwise low PRS and distinct correlations with measured biochemical traits. In 54 55 summary, genetic risk could be used more specifically to direct drug repurposing candidates 56 that target particular genes implicated in psychiatric and other complex disorders.

- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- --
- 65
- 66
- 67

68 INTRODUCTION

Psychiatric disorders remain difficult to effectively manage in some patients, with treatment 69 70 resistance observed in a notable proportion of individuals prescribed conventional pharmacotherapies [1-3]. Moreover, a key challenge in psychiatric practice is the selection of 71 72 a suitable course of treatment for newly diagnosed patients. Novel treatment opportunities for these disorders would be of great clinical benefit, however, the drug development pipeline 73 74 remains arduous, expensive, and unproductive [4, 5]. Drug repurposing, whereby an approved compound is redeployed for a new indication, is a promising avenue to more rapidly alter 75 76 psychiatric practice relative to the *de novo* drug development process [6, 7]. There has already 77 been utility in this approach demonstrated in psychiatry, such as atomoxetine that has been 78 repurposed for attention-hyperactive deficit disorder (ADHD) and the anti-convulsant 79 valproate for bipolar disorder [8].

80

We know that psychiatric illnesses arise from a multifaceted interplay between genetic and 81 82 environmental factors that contribute to its aetiologic complexity. In recent years, genomewide association studies (GWAS) have confirmed that psychiatric disorders are polygenic in 83 84 nature [9–13], with common frequency variants constituting a significant portion of trait 85 heritability. This means that individual loci that have small to modest impact, but contribute to a much larger polygenic effect of many such variants throughout the genome [14, 15]. 86 87 Biological insights from genetic studies could lead to repurposing opportunities in psychiatry - for example, schizophrenia GWAS have previously suggested that the common variant signal 88 89 is enriched amongst the targets of antiepileptics, as well as in genes involved in retinoid (vitamin A derivative) pathways [16, 17]. The polygenic nature of these disorders, however, 90 91 present a challenge drug targeting because the genetic architecture of each individual will be 92 highly heterogeneous. This means that any given patient will carry a unique combination of 93 risk and protective alleles, which likely translates to different underlying biological processes 94 being affected. As a result, genetically informed drug candidates may not be efficacious at a population level. These phenomena necessitate the consideration of how pharmacotherapies 95 96 could be targeted more specifically to individuals based on their underlying genetic and clinical 97 risk factors.

98

Our group has previously sought to address these challenges through the development of the
 pharmagenic enrichment score (PES), which is a framework that seeks to use polygenic risk
 to direct precision drug repurposing opportunities [7, 18–20]. Specifically, the PES approach

102 derives partitioned polygenic scores from variants annotated to pathways or networks that are targeted by approved drugs, with the underlying hypothesis that individuals with elevated 103 104 genetic risk (PES) amongst those genes may benefit from a compound which modulates that pathway. Furthermore, in prior work we have established that PES profiles provide distinct 105 106 insights from a biologically undifferentiated genome-wide polygenic risk score (PRS) [18–20]. However, a limitation of the PES approach is that it is not innately informative as to which of 107 108 the suite of drugs targeting a pathway will be most useful, particularly in regards as to whether an agonist or antagonist of target genes should be investigated. While we addressed this 109 110 previously, in respiratory medicine, by triangulating prioritised pathways through causal inference of pharmacologically sensitive biochemical traits [19, 20], these relationships are 111 112 more difficult to find in psychiatric disorders [21]. In the current study, we propose a new implementation of the PES that is informed by genetically proxied mRNA or protein 113 expression of drug target genes. This approach identifies candidate psychiatric drug 114 repurposing opportunities at the population level that can then be more appropriately integrated 115 116 with genetic risk scores relevant to these target genes, to identify individuals who may benefit more readily from these compounds. These are termed *directional anchor genes* as they inform 117 118 on the clinically useful direction of modulation is for the biological networks containing these 119 genes which can be utilised to construct PES. In this study, we investigated this novel approach in two highly heritable psychiatric disorders, schizophrenia and bipolar disorder, and identified 120 121 novel drug repurposing opportunities from candidate directional anchor genes and propose how these genes could be used in concert with the PES to direct the candidate compounds for 122 123 repurposing.

124

125 MATERIALS AND METHODS

126

127 Overview of the directional anchor gene *pharmagenic enrichment score* approach

We summarise the fundamental principles of directional anchor genes and their integration 128 with the *pharmagenic enrichment score* in this section, followed by more expansive details in 129 130 the subsequent sections. Briefly, we define the concept of a directional anchor gene (DA-gene) as a gene where, i) the direction of expression associated with increased odds of the disorder 131 132 can be predicted, and ii) this disorder associated direction of expression could be counteracted 133 by an approved compound, thus constituting a drug repurposing opportunity. For instance, if 134 upregulation of a hypothetical gene, gene X, was associated with greater odds of a disease phenotype, then an antagonist of gene X may be clinically useful. If this gene X antagonist is 135

136 already approved for another indication, this may inform drug repurposing. However, there is immense heterogeneity between individuals for any given complex trait or disease in its genetic 137 138 architecture, which often translates to highly variable clinical manifestation. We therefore hypothesise that individuals with a greater burden of disorder-associated polygenic risk in the 139 140 directional anchor gene, and its network of genes that physically and biologically interact with it, may benefit more specifically from a drug repurposing candidate targeting the DA-gene. 141 142 Polygenic risk mapped to biological networks encompassing the directional anchor genes is likely to incorporate disorder-associated impacts on upstream processes that would modify the 143 effect of a compound targeting the candidate gene, as well as downstream processes triggered 144 by modulating the directional anchor. As discussed in the introduction, our group has 145 previously developed the pharmagenic enrichment score (PES) methodology to utilise 146 147 polygenic scoring to direct drug repurposing, whereby polygenic scores are constructed specifically using variants mapped to biological pathways targeted by known drugs [18, 19]. 148 A limitation of the PES approach is that it does not inherently predict the direction of effect 149 genes in the pathway that would need to be targeted such that repurposing a drug for individuals 150 151 with high polygenic risk in said pathway would be efficacious. Directional anchor genes, 152 therefore, help address this limitation when used in conjunction with PES constructed using 153 networks or biological pathways in which the gene participates. In other words, drug 154 repurposing opportunities are predicted at the population level based on the expression of target 155 genes, with these compounds potentially able to be more specifically directed to individuals with elevated disorder associated genetic risk within pathways or networks that contain the 156 157 directional anchor gene, that is, an elevated PES (Figure 1). It should be noted that whilst we apply this approach to binary disease phenotypes in this study, it can also be utilised for 158 159 clinically relevant continuous traits. In that case, candidate directional anchor genes would be those genes for which the drug repurposing candidate is genetically inferred to modulate the 160 161 trait in a clinically useful fashion.

162

163

164



199 Figure 1. Overview schematic of the integration of candidate directional anchor

genes with pharmagenic enrichment scores. Directional anchor genes are genes 200 201 targeted by an approved compound in what is genetically predicted through integration with expression data to decrease the risk of the disorder or modulate the trait, if 202 203 continuous, in a clinically useful manner. For instance, if increased expression of a gene 204 is associated with a disorder through a transcriptome or proteome-wide association 205 study (TWAS/PWAS) or Mendelian randomisation (MR) using quantitative trait loci as instrumental variables, then an antagonist of said gene may be a repurposing 206 207 opportunity. Directional anchor genes then act as seed genes to define a network of other genes that interact with them. SNPs mapped to this network are then utilised to 208 209 construct a pharmagenic enrichment score (PES) for the network. In the case of a 210 binary disease phenotype, the interpretation of the PES would be that individuals with an elevated score relative to an appropriate population reference may benefit from a 211 compound which modulates the directional anchor gene. The hypothesis underlying 212 213 this is that these individuals will have genetic risk that impacts upstream or downstream processes relating to the directional anchor, as well as the anchor gene itself, which 214 215 could be addressed by the repurposing candidate in question.

216

217 Schizophrenia and bipolar disorder genome-wide association studies

We obtained GWAS summary statistics for schizophrenia (SZ) and bipolar disorder (BIP) from the psychiatric genomics consortium [9, 10]. The SZ GWAS was a mega-analysis of mostly European ancestry cohorts and comprised 67,390 cases and 94,015 controls, whilst the European ancestry BIP GWAS mega-analysis had 20,352 cases and 31,358 controls. In addition, we also utilised the same SZ GWAS with a constituent cohort removed (Australian Schizophrenia Research Bank) when we profiled PES within that dataset, as described in a proceeding section of the methods.

225

226 Transcriptome and proteome-wide association studies

A transcriptome-wide association study (TWAS) and a proteome-wide association study (PWAS) was performed of SZ and BIP by leveraging genetically imputed models of mRNA and protein expression, respectively. Specifically, we utilised the FUSION approach for TWAS/PWAS, with full details outlined in the supplementary materials [22]. Expression weights for the TWAS were derived from postmortem brain (GTEx v7, PsychENCODE) and whole blood (GTEx v7), whilst protein expression weights were similarly from postmortem

brain (ROSMAP) and whole blood (ARIC) [22-25]. The FUSION methodology integrates 233 234 SNP-effects from the model of genetically predicted expression with the effects of the same 235 SNPs on SZ or BIP, after accounting for linkage disequilibrium, such that the TWAS Z score can be a conceptualised measure of genetic covariance between mRNA or protein expression 236 237 of the gene and the GWAS trait of interest. We utilised a conservative method for multipletesting correction whereby the Bonferroni methodology was implemented to divide the alpha 238 239 level (0.05) by the total number of significantly *cis*-heritable models of genetically regulated 240 expression (GReX) tested from any brain tissue considered or whole blood (Supplementary 241 Text, Supplementary Tables 1-4). Several genes had GReX available in multiple-tissues, thus rendering Bonferroni correction conservative, however, we implemented this approach to 242 243 capture only the most confidently associated genes that could constitute drug-repurposing 244 candidates. For candidate directional anchor genes derived from TWAS/PWAS, we probabilistically finemapped those regions using the FOCUS methodology using the default 245 prior ($p = 1 \ge 10^{-3}$) and prior variance ($n\sigma^2 = 40$) to approximate Bayes' factors, such that the 246 posterior inclusion probability (PIP) of each gene being a member of a credible set with 90% 247 248 probability of containing the causal gene could be derived [26]. We also investigated the impact of using a more conservative prior as outlined in the supplementary text. Moreover, we tested 249 250 whether SNPs that constitute the GReX model and either SZ or BIP displayed statistical colocalisation with the *coloc* package as implemented by FUSION [27]. 251

252

253 Mendelian randomisation

254 In addition, we leveraged variants strongly correlated with mRNA (expression quantitative trait 255 loci – eQTL) and protein expression (protein expression quantitative trait loci – pQTL), 256 respectively, as instrumental variables (IVs) in a two-sample Mendelian randomisation (MR) analysis [28]. Analogous to the TWAS/PWAS, eQTL/pQTL were derived from brain 257 258 (MetaBrain, ROSMAP) and blood (eQTLGen, Zhang et al.), with full details described in the supplementary text [28–31]. Strict selection criteria were implemented to select suitable IVs, 259 including only retaining independent genome-wide significant ($P < 5 \ge 10^{-8}$) SNPs that were 260 261 associated with three or less mRNA/proteins in each relevant tissue/study (Supplementary 262 Text). Moreover, we utilised a more stringent LD clumping procedure for eQTLs given the greater power and sample sizes for these datasets also results in immense pleiotropy amongst 263 264 the SNP effects on mRNA. This was achieved by only selecting the most significant independent SNPs using one megabase clumps, with LD estimated using the 1000 genomes 265 266 phase 3 panel. The effect of mRNA or protein expression for any given gene on SZ or BIP was

267 estimated using the Wald ratio (single IV) or an inverse-variance weighted estimator (multiple IVs, with fixed effects due to the small number of IVs). As in the TWAS/PWAS, we utilised 268 269 Bonferroni correction across all tissues in the mRNA and protein analyses respectively and then sought to identify candidate directional anchor genes from these signals. For any candidate 270 271 directional anchor genes, where an approved drug was predicted to reverse the odds increasing 272 direction of expression, we performed a series of sensitivity analyses (Supplementary Text). 273 Briefly, these involved: assessing the genomic locus of the IV SNP, for genes it may be associated with, by testing for evidence of a shared causal variant through colocalisation 274 275 (default priors) and conducting a phenome-wide Mendelian randomisation analysis (MRpheWAS) using SNP effects from each trait in the IEUGWAS database. The above MR and 276 277 sensitivity analyses were performed using the R packages TwoSampleMR v0.5.5, ieugwasr 278 v0.1.5, and coloc v4.0.4 [27, 32].

279

280 Identifying drug repurposing candidates

We searched genes prioritised from the TWAS/PWAS or MR analyses in the Drug-gene interaction database (DGIdb v4.2.0 – accessed April 2021) to identify approved compounds that could reverse the odds increasing direction of expression for SZ or BIP [33]. DGIdb combines data from databases such as DrugBank, as well as curated literature sources. We defined high confidence drug-gene interactions as those reported in DrugBank as well as at least one other database or literature source.

287

288 Identification of genes interacting with candidate directional anchor genes

Protein-protein interaction data was downloaded from the STRING database v11 [34]. We 289 290 utilised each of the six candidate directional anchor genes as a seed gene, separately, and 291 constructed a network of genes predicted to interact with the seed gene by retaining high 292 confidence edges (confidence score > 0.7) derived from experimental evidence or curated 293 protein-complex and pathway databases, as this is generally considered the most rigorous evidence from STRING. We then tested which gene-sets curated by the g:Profiler (version 294 e104 eg51 p15 3922dba) resource (GO, KEGG, Reactome, WikiPathways, TRANSFAC, 295 296 miRTarBase, Human Protein Atlas, CORUM, and Human phenotype ontology) were overrepresented amongst the genes in each network, using the g:SCS (set counts and sizes) 297 multiple-testing correction method implemented by g:Profiler that has been shown to better 298 299 account for the complex, overlapping nature of these data [35]. We considered a corrected P 300 value < 0.05 as significant.

301 We then tested the association of the genes in each of these networks, with and without the gene removed, with the common variant signal in the SZ and BIP GWAS using MAGMA 302 303 v1.09 [36]. Briefly, SNP-wise P values were aggregated at gene-level, with SNPs annotated to genes using two different sets of genic boundary extensions to capture potential regulatory 304 305 variation, conservative (5 kilobases (kb) upstream, 1.5 kb downstream), and liberal (35 kb upstream, 10 kb downstream). Gene-set association is implemented by MAGMA using linear 306 307 regression, whereby the probit transformed genic P values (Z scores) are the outcome with a 308 binary explanatory variable indicating whether a gene is in the set to be tested (β_s), covaried 309 for other confounders like gene size, as described previously. The test statistic of interest is a 310 one-sided test of whether $\beta_S > 0$, and thus, quantifies if the genes in the set are more associated than all other genes. We also investigated the association of the approximately 34,000 gene-311 312 sets collated by g:Profiler, such that we could demonstrate whether gene-sets overrepresented 313 in each network were also associated with SZ or BIP.

314

315 Constructing directional anchor gene network PES

We sought to utilise variants annotated to the genes within the network of each candidate directional anchor genes to develop *pharmagenic enrichment scores* for SZ and BIP, respectively. As described previously, a PES is analogous to a genome-wide PRS in its derivation, with the key defence that it only utilises variants mapped to the gene-set of interest (equation 1) [18]. Specifically, a PES profile in individual *i* comprises the sum of the effect size of *j* variants from the GWAS ($\hat{\beta}_j$) annotated to at least one gene in set *M*, multiplied by the allelic dosage under an additive model ($G_{ij} \in G = 0, 1, 2$).

323
$$PES_i = \sum_{j=1}^{M} \hat{\beta}_j G_{ij}$$
 [1]

324

The genome wide PRS for SZ and BIP are essentially the same model but *M* incorporates the 325 326 entire genome. In accordance with the MAGMA analyses, we tested two genic boundary configurations for evaluating the best performing PES for each directional anchor gene network 327 - conservative and liberal. Our previous PES related approaches utilised the LD clumping and 328 329 thresholding (C+T) approach, whereby SNPs are 'clumped' such that the retained SNPs are largely independent and 'thresholded' based on their association P-value in the GWAS. In each 330 331 case the threshold was set at the optimum for the druggable gene-set association at the 332 population level. However, given we selected the gene-sets in this study based on interactions

333 with the candidate directional anchor gene, we tested four different P value thresholds $(P_T \in T = \{0.005, 0.05, 0.5, 1\})$, which represent a model with all SNPs, nominally significant 334 SNPs, and a threshold an order of magnitude above or below the nominal threshold. These 335 336 choices of T have been discussed extensively elsewhere [18-20]. We utilised PRSice-2 v2.3.3 (linux) for the C+T models [37]. In addition, we utilised a penalised regression framework to 337 shrink SNP effect sizes to optimise the model for each PES, as implemented by the standalone 338 339 version of lassosum v0.4.5 [38]. The implementation for this method has been outlined 340 extensively elsewhere, with the optimal tuning parameter (λ) based on the score that displays the highest correlation with the phenotype and the best performing constraint parameter (s)341 chosen from a range of a priori specified values to decrease computational burden (0.2, 0.5, 342 343 0.9, and 1).

344

345 Training and validation of directional anchor gene network PES

We utilised the prospective UK Biobank (UKBB) cohort to define the best performing PES for 346 347 each directional anchor gene network. Our group has previously processed the UKBB genotype data such that unrelated individuals of white British ancestry were retained, along with other 348 349 sample and variant level quality control considerations applied [20]. As a result, the composition of the full UKBB cohort in this study was 336,896 participants for which up to 350 351 13,568,914 autosomal variants were available (imputation INFO > 0.8). SZ and BIP cases were 352 defined in the UKBB using a combination of self-report data both from the general assessment 353 visit and the mental health questionnaire (MHQ), along with hospital inpatient data (primary or secondary ICD-10 codes), with full details in the supplementary text. In total, there were 354 355 631 UKBB participants from the study cohort defined as having SZ, with 1657 BIP cases identified. The controls were double the number of the respective case cohorts randomly, and 356 357 independently for SZ and BIP, derived from 75,201 individuals with genotype data that 358 completed the MHQ and did not self-report any mental illness. The full complement of SZ 359 cases with the aforementioned controls (N = 1262) was utilised as the training set for the SZ scores given the relatively small number of cases. As a result, we utilised the Australian 360 Schizophrenia Research Bank (ASRB) cohort as a validation set to attempt to replicate the 361 362 associations observed with the scores, which has been described elsewhere [18, 39]. The ASRB 363 was a component of the PGC3 SZ GWAS, and thus, we retrained all the best performing PES scores using summary statistics with the ASRB cohort removed before testing them in that 364 365 dataset. The BIP analyses employed a 70/30 split for the training and validation cohort in the

366 UKBB, with double the number of independent MHQ derived healthy controls utilised for each
367 case-set. Further information regarding the demographic composition of these cohorts is
368 provided in the supplementary text.

369

370 The PES and PRS constructed using the C+T configurations and penalised regression were scaled to have a mean of zero and unit variance before evaluating their association with SZ or 371 372 BIP, for the respective scores in the UKBB training cohorts, using binomial logistic regression covaried for sex, age, genotyping batch, and five SNP derived principal components. The 373 374 optimal PES for each network was selected for each disorder separately by calculating the variance explained on the liability scale (Nagelkerke's R^2), assuming a 0.7% and 1% 375 prevalence for SZ and BIP, respectively [40]. These PES/PRS that explained the most 376 377 phenotypic variance were then profiled and tested in the validation sets. For PES that were significantly associated with either disorder, we conservatively constructed another model that 378 also included genome wide PRS, with a χ^2 test of residual deviance performed to ascertain 379 whether adding the PES in addition to the PRS significantly improved model fit. Correlations 380 381 (Pearson's) amongst scaled PES and PRS were visualised using the corrplot package v0.84. Individuals with at least one elevated PES in the training cohorts (highest decile) were 382 383 identified, with this binary variable tested for association with SZ or BIP using another logistic 384 regression model. Finally, we also considered residualised PES, whereby the residuals were extracted and scaled from a linear model that regressed genome wide PRS against principal 385 386 components and genotyping batch on the score in question. All analyses described in this 387 paragraph were performed utilising R v3.6.0.

388

389 Biochemical and mental health phenome-wide association studies

We then investigated the correlations between the best performing PES for each network and 390 391 i) blood or urine biochemical traits, and ii) self-reported mental health disorders besides SZ or BIP. The biochemical analyses were performed in up to 70,625 individuals who did not self-392 393 report any mental health disorders in the MHQ and were also not included in the SZ or BIP training/validation sets as controls. There were 33 biochemical traits tested (raw values -394 395 Supplementary Table 5) in a linear model with each PES or PRS as an explanatory variable covaried for sex, age, sex x age, age², 10 principal components, and genotyping batch. We also 396 397 performed sex-stratified analyses, with oestradiol additionally considered in females. A number of sensitivity analyses were performed for PES-biochemical trait pairs that were 398 399 significantly correlated after FDR correction- i) adjustment for genome-wide PRS, ii) natural

400 log transformation of the biochemical outcome variable, iii) inverse-rank normal transformed residuals as the outcome variable from a model that regressed sex, sex x age, and age², and iv) 401 402 adjustment for statin use (given the number of lipid related signals uncovered). These 403 correlations are observational in nature, and thus, there are several other potential confounders that could be considered - however, given the potential biases induced by adjusting for 404 heritable covariates, we utilised the above strategies as a baseline suite of sensitivity analyses 405 406 [41]. A specific test of sexual dimorphisms between the regression results in males and females was also performed based on the sex-specific regression estimates and standard errors, as 407 408 outlined elsewhere [42]. Moreover, we then evaluated the association between each score and 409 14 non-SZ or BIP mental health disorders which individuals who completed the MHQ were 410 asked to self-report (Supplementary Table 6). In all instances, we used the 70,625 individuals who did not self-report any mental disorders as the controls in binomial logistic regression 411 412 models covaried for the same terms as in the biochemical analyses.

413

414 **RESULTS**

415

416 Candidate directional anchor genes reveal novel drug repurposing opportunities in417 psychiatry

We sought to identify candidate directional anchor genes for SZ or BIP by integrating GWAS 418 419 summary statistics for these traits with transcriptomic and proteomic data collected from either blood or post-mortem brain (Figure 2a). Specifically, we utilised genetically imputed models 420 421 of mRNA or protein expression to conduct a TWAS and PWAS, respectively (Supplementary 422 Tables 1-4). Genome-wide significant eQTLs and pQTLs were also leveraged as instrumental 423 variables in a more conservative two-sample Mendelian randomisation analysis to explicitly test for any causal effects of mRNA or protein expression (Supplementary Tables 7-10). After 424 425 implementing Bonferroni correction within each analysis set (TWAS, PWAS, eQTL-MR, 426 pQTL-MR), we found several genes for which their expression was associated with at least one of the psychiatric phenotypes at the mRNA or protein level that was also putatively 427 428 modulated by an approved compound in a risk decreasing direction. There were 13 druggable 429 genes from TWAS for which the direction of genetically predicted mRNA expression correlated with SZ could be pharmacologically counteracted, whilst there were two such genes 430 431 for BIP, some examples of which are visualised in Figure 2b. For instance, imputed mRNA 432 expression of the calcium voltage-gated channel subunit gene CACNAIC was negatively correlated with SZ ($P = 3.65 \times 10^{-15}$), and thus, an activator of this gene like the antiarrhythmic 433

434 agent Ibutilide may be a repurposing candidate for SZ, with this gene also trending towards association with BIP in the same direction ($P = 3.18 \times 10^{-5}$). We compared the TWAS results 435 436 to that of a PWAS using data from blood or brain tissue, although the number of proteins 437 assayed in these studies was considerably smaller than that of the number of mRNA available, 438 and thus, most of the candidate genes derived using TWAS did not have protein measurements available for a direct comparison of the effect of protein expression relative to mRNA. 439 440 However, there were two Bonferroni significant TWAS genes that represented a plausible repurposing candidate with protein expression data available (NEK4 and CTSS), with both 441 genes showing a similar strength of association in the PWAS. For any given genetically 442 443 predicted mRNA or protein expression, the gene is not necessarily causal due to LD complexity and other phenomena such as co-regulation [43]. This is critical for using these approaches to 444 445 direct drug repurposing as the target the genes need to correspond to the genetic association for the disorder. As a result, we implemented a Bayesian finemapping procedure for each TWAS 446 447 candidate gene to identify plausible causal genes in each locus (Supplementary Text). We found four repurposing candidate genes for SZ with strong evidence for membership of a 448 credible set with 90% probability of containing the causal gene (PIP > 0.8 - PCCB, GRIN2A, 449 FES, and CACNAID). However, CACNAID was excluded from further analyses due to the 450 451 poor performance of its imputed model and complexity of its locus on chromosome three, as 452 outlined more extensively in the supplementary text. We then considered a more lenient 453 posterior inclusion probability of 0.4, which identified two more genes for SZ (CACNA1C and RPS17), and a BIP gene (FADS1). Colocalisation analyses were also performed to test a 454 455 related, but distinct hypothesis that the GWAS signal and SNP weights in the expression model 456 share an underlying single causal variant. Interestingly, for the genes selected using the lower confidence PIP > 0.4 threshold, we found strong evidence for a shared causal variant ($PP_{H4} >$ 457 0.9), supporting their inclusion as putative drug repurposing targets. We did not consider the 458 459 two genes shared with the PWAS any further as they did not display strong finemapping 460 support in the TWAS, which is a more accurate representation of any given locus due to the more expansive number of genes with RNAseq available. In summary, using a genetically 461 imputed expression approach we identified five candidate directional anchor genes for SZ and 462 463 one for BIP (Table 1). For example, imputed GRIN2A mRNA expression was negatively correlated with SZ ($P = 1.44 \text{ x } 10^{-9}$), with a trend also observed for BIP ($P = 5.07 \text{ x } 10^{-3}$), with 464 compounds of interest in psychiatry, such as N-acetylcysteine, known to agonise this subunit 465 466 [44, 45].

467



502

Figure 2. Identification of candidate directional anchor genes for schizophrenia 503 504 and bipolar through integration of transcriptomic and proteomic data. (a) 505 Schematic for the prioritisation of candidate directional anchor genes through models of genetically regulated expression (GReX, yellow) and Mendelian randomisation 506 (orange). In both instances, approved compounds are derived for implicated genes that 507 508 reverse the odds increasing direction of mRNA or protein expression. TWAS = transcriptome-wide association study, PWAS = proteome-wide association study (b) 509 510 Results of the multi-tissue (brain and blood) TWAS for schizophrenia (SZ, top) and bipolar disorder (BIP, bottom). The Miami plot visualises the $-\log 10$ transformed P 511 512 value of association with genes exhibiting a negative genetic covariance between 513 expression and the trait, that is, TWAS Z < 0, plotted in the downward direction. The red line denotes the Bonferroni threshold. The candidate directional anchor genes from 514 the TWAS approach are highlighted on the plot along with their putative repurposing 515 candidate that corrects the odds-increasing direction of expression. For example, 516 predicted PCCB expression is negatively correlated with SZ, and thus, a PCCB agonist 517 518 like biotin may be clinically useful.

519

520 To prioritise candidate directional anchor genes, we utilised eQTL and pQTL as IVs to estimate 521 the causal effect of mRNA or protein expression on either disorder outcome in a Mendelian randomisation analysis, given more onerous assumptions are met (Supplementary Materials, 522 523 Supplementary Tables 7-10). This is critical as the use of molecular QTLs related to variables 524 like mRNA expression as IVs is challenging due to LD complexity and the potential effect of 525 QTLs on multiple genes [28, 46]. As a result, we sought to complement the above discovery 526 orientated TWAS/PWAS with more conservative selection criteria for an eQTL or pQTL to be 527 an IV, particularly in the case of eQTLs where sample sizes for some tissues are now very large. Independent SNPs (LD $r^2 < 0.001$) acting as eQTLs or pQTLs at a threshold of genome-528 wide significance ($P < 5 \ge 10^{-8}$) were selected from post-mortem brain or blood, as outlined in 529 530 the methods and supplementary materials. Due to the conservative nature of these analyses, 531 many of the genes considered in the TWAS/PWAS did not have a suitable IV available. Conversely, a small number of genes that did not display adequate multivariate *cis*-heritability 532 in the TWAS/PWAS weights could now be included. The mRNA models after Bonferroni 533 534 correction uncovered four genes for which expression exerted a potential causal effect on SZ or BIP with a suitable compound approved to reverse the odds-increasing direction of effect. 535

536 There were three for SZ (PCCB, NEK1, and PTK2B), as well as FADS1 for bipolar. 537 Interestingly, PCCB and FADS1 overlapped with the TWAS results – as an example, each 538 standard deviation increase in cortical FADS1 expression was associated with approximately 539 15.23% [95% CI: 8.69%, 21.77%] decrease in the odds of BIP, which could be accentuated by 540 a FADS1 agonist like the omega-3 fatty acid supplement icosapent (Ethyl eicosapentaenoic acid). We then performed a series of sensitivity analyses to assess IV validity and for evidence 541 542 of confounding pleiotropy (Supplementary Materials). These analyses supported PCCB and FADS1 as candidate directional anchor genes. The index IV-SNPs mapped to PCCB and 543 544 FADS1 expression, respectively, was then utilised to perform a phenome-wide scan spanning 545 over 10,000 GWAS of the effect of expression of these two genes using SNP effect sizes from the IEUGWAS database (Supplementary Tables 11-13). Firstly, we found that increased 546 547 cortical expression of PCCB, which was associated with deceased odds of SZ from a previous 548 GWAS, was also linked to a reduction in other psychiatric phenotypes from self-reported UK Biobank GWAS such as worry, neuroticism, nervousness, and tenseness, supporting the utility 549 550 of a PCCB agonist, like biotin, as a repurposing candidate. Secondly, the phenome-wide data 551 for increased cortical FADS1 expression demonstrated, as expected, a strong effect on lipids, 552 including increased HDL and decreased triglycerides. While another candidate for BIP 553 (MAP2K2) was suggested as a trans-pQTL by this approach, it was excluded to retain the most 554 biologically confident associations. Although the MR approach did not add any additional 555 candidate directional anchor genes (after exclusion of MAP2K2), it provided more support to PCCB and FADS1. A less conservative MR paradigm in terms of IV selection would likely 556 yield more genes but as our TWAS/PWAS analyses were already discovery focused, we 557 558 believe this would not be appropriate given the underlying assumptions of MR. We summarise 559 the candidate directional anchor genes in table 1.

- 560
- 561
- 562
- 563
- 564
- 565
- 566
- 567
- 568
- 569

570 Table 1. Candidate directional anchor genes for schizophrenia and bipolar along with

571 their associated drug repurposing candidates.

572

Gene	Disorder	Protective direction	Repurposing candidates	Sensitivity analyses
РССВ	SZ	Increased expression	Biotin	High confidence causal gene from TWAS (<i>PIP</i> > 0.8). Further supported by MR
FADSI	BIP	Increased expression	Icosapent Linolenic acid	Moderate confidence causal gene from TWAS (<i>PIP</i> > 0.4, additionally supported by colocalisation – PP_{H4} > 0.8). Further supported by MR
GRIN2A	SZ	Increased expression	N-acetylcysteine Glycine	High confidence causal gene from TWAS (<i>PIP</i> > 0.8).
CACNAIC	SZ	Increased expression	Ibutilide	Moderate confidence causal gene from TWAS (<i>PIP</i> > 0.4 , additionally supported by colocalisation – $PP_{H4} > 0.8$).
RPS17	SZ	Increased expression	Artenimol	Moderate confidence causal gene from TWAS ($PIP > 0.4$, additionally supported by colocalisation – $PP_{H4} > 0.8$).
FES	SZ	Decreased expression	Fostamatinib Lorlatinib	High confidence causal gene from TWAS (<i>PIP</i> > 0.8).

573

574

575 Interaction networks related to directional anchor genes capture biology associated with 576 schizophrenia and bipolar disorder

577 We sought to define a network of genes that display high confidence interactions with each candidate directional anchor gene using data from the STRING database, such that we can then 578 579 construct a *pharmagenic enrichment score* using variants annotated to these genes. The number of direct interactions identified for each of the six candidate genes, excluding the gene itself, 580 581 were as follows (Supplementary Tables 14): CACNA1C network (83 genes), FADS1 network (16 genes), FES network (37 genes), GRIN2A network (54 genes), PCCB network (26 genes), 582 and RPS17 network (254 genes). All of these networks displayed significantly more 583 interactions than what would be expected by chance alone ($P < 1 \ge 10^{-16}$, Supplementary Table 584 15), with an example of two of these networks (CACNA1C and FADS1) visualised in Figure 585

586 3a. These networks likely represent heterogenous biological processes in which the directional anchor gene may participate, and thus, we sought to better understand the biology of these 587 588 interacting genes by testing their overrepresentation within biological pathways and other ontological gene-sets. The six directional anchor gene networks each displayed 589 overrepresentation in pathways related to the known biology of the candidate gene 590 (Supplementary Tables 16-21). For instance, the CACNA1C network genes were enriched 591 592 within several hundred gene-sets, many of which related to neuronal calcium channel biology 593 along with systemic processes known to involve calcium signalling such as pancreatic insulin 594 secretion. Furthermore, the FADS1 network genes displayed an overrepresentation in several 595 lipid and other metabolic related pathways, whilst GRIN2A network genes demonstrated a 596 strong link to neuronal biology.

597

We then tested whether there was enrichment of the common variant signal for SZ or BIP in 598 any of these networks, with and without the directional anchor gene included, using MAGMA 599 600 (Figure 3b, Supplementary Table 22). The CACNA1C network was strongly associated with SZ ($P = 8.87 \times 10^{-8}$), even after removing CACNA1C itself ($P = 1.19 \times 10^{-6}$). The FES and 601 602 GRIN2A networks demonstrated a nominal enrichment of the SZ common variant signal relative to all other genes, $P = 1.28 \times 10^{-3}$ and P = 0.014, respectively, remaining significant 603 604 upon removing the relevant directional anchor genes. None of the other networks were 605 associated with SZ when considering all genes, with only the FADS1 network demonstrating a nominal association with BIP (P = 0.04). Given that these networks represent several different 606 607 biological processes, we further hypothesised that specific gene-sets for which they were overrepresented may specifically display a stronger association with SZ or BIP (Supplementary 608 609 Tables 23-28). Indeed, we show that all of the networks had at least one overrepresented 610 pathway that was associated with SZ or BIP using Bonferroni (FWER < 0.05) and Benjamini-611 Hochberg (FDR < 0.05) correction, with the exception of the sets enriched in the *PCCB* 612 network that only survived correction using FDR. Kernel density estimation plots of the MAGMA gene-set association P values are visualised in figure 3c, which show pathway-613 associations reaching these thresholds. We briefly describe the results for the CACNA1C and 614 *GRIN2A* networks below for illustration. Pathways overrepresented in the *CACNA1C* network 615 616 related to calcium channel activity displayed strong association with SZ, for instance, voltage gated calcium channel process ($P = 2.80 \times 10^{-10}$, $q = 6.83 \times 10^{-7}$), whilst the regulation insulin 617 secretion pathway that also was enriched in the network was associated with SZ and trended 618 towards surviving multiple testing correction for BIP. GRIN2A network members also 619

displayed an enrichment amongst several neuronal pathways strongly associated with SZ, such as synaptic signalling ($P = 3.88 \times 10^{-8}$, $q = 2.82 \times 10^{-5}$). Taken together, these results suggest that pathways in which genes in each network participate are associated with psychiatric illness and reinforces the biological salience of these networks.

medRxiv preprint doi: https://doi.org/10.1101/2022.03.20.22272666; this version posted March 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC 4.0 International license .



687 Figure 3. Biological networks interacting with candidate directional anchor genes. (a) Visualisation of two networks of genes that putatively interact with CACNA1C (left) 688 689 and FADS1 (right) based on experimental and curated database evidence. Blue edges 690 represent evidence from curated databases, whilst purple edges denote experimentally 691 determined evidence. (b) Gene-set association (MAGMA) of the entire network for 692 each candidate directional anchor (DA) gene, with and without the DA gene included 693 from the model. Dotted line represents nominal significance (P < 0.05). The MAGMA P value is derived from a model which tests whether the common variant signal within 694 695 genes in the network is greater than what is observed amongst all remaining genes. Two 696 genic boundaries were utilised to annotate SNPs to genes from the GWAS: conservative (5kb upstream, 1.5 kb downstream, left panel) and liberal (35 kb upstream, 10 kb 697 698 downstream, right panel). (c) Kernel density estimation plots of the MAGMA gene-set association P value for each gene-set tested using either schizophrenia or bipolar 699 700 results, whichever was more significant, which had a significant overrepresentation of 701 genes within that network. The dotted line represents the Bonferroni significance level 702 for approximately 34,000 gene-sets considered in the full analysis of all gene-sets that 703 were tested for overrepresentation.

- 704
- 705

706 Directional anchor gene network pharmagenic enrichment scores display significant trait 707 associations after adjustment for genome-wide polygenic risk score

708 Pharmagenic enrichment scores (PES) were then constructed for the genes in each directional 709 anchor gene network using SNP weights for SZ and BIP, respectively. SZ and BIP PES were 710 considered for all six networks given the high genetic correlation between SZ and BIP, as well as extensive phenotypic overlap. We defined a training set of SZ (N = 631) and BIP cases (N 711 712 = 1161) in the UK Biobank, with double the number of controls randomly, and independently, 713 selected from individuals with no self-reported mental health conditions for each training set. Two methods were utilised to find the most parsimonious PES profile for each network, along 714 with a genome-wide PRS for SZ and BIP - clumping and thresholding (C+T), and penalised 715 716 regression (Table 2).

- 717
- 718
- 719

720 Table 2. Characteristics of the best performing schizophrenia and bipolar genome wide

721 PRS along with a *pharmagenic enrichment score* for each directional anchor gene network

Score	N _{SNPs} ¹	Beta (SE) ²	Р	R^2	Type ³				
Bipolar disorder									
PRS	1096096	0.62 (0.04)	2.91x10 ⁻⁵¹	4.96%	Penalised regression				
CACNA1C network	396	0.11 (0.04)	2.97x10 ⁻³	0.16%	Penalised regression				
FADS1 network	196	0.06 (0.04)	0.1	0.05%	C+T				
FES network	5	0.10 (0.04)	4.87x10 ⁻³	0.14%	Penalised regression				
GRIN2A network	143	0.17 (0.04)	3.81x10 ⁻⁶	0.39%	Penalised regression				
PCCB network	520	0.14 (0.04)	2.22x10 ⁻⁴	0.25%	Penalised regression				
RPS17 network	13724	0.15 (0.04)	1.07x10 ⁻⁴	0.28%	Penalised regression				
Schizophrenia									
PRS	1861450	1.01 (0.07)	2.65x10 ⁻⁵¹	9.55%	Penalised regression				
CACNA1C network	128	0.09 (0.05)	0.1	0.09%	C+T				
FADS1 network	36	0.04 (0.05)	0.4	0.02%	C+T				
FES network	141	0.17 (0.05)	1.41x10 ⁻³	0.32%	C+T				
GRIN2A network	5037	0.18 (0.05)	9.23x10 ⁻⁴	0.35%	Penalised regression				
PCCB network	2393	0.07 (0.05)	0.16	0.06%	Penalised regression				
RPS17 network	77	0.15 (0.05)	3.53x10 ⁻³	0.27%	Penalised regression				

⁷²²

¹SNPs with a non-zero coefficient after reweighting in the penalised regression model or independent SNPs after linkage disequilibrium clumping and thresholding (C+T).

²Bipolar disorder or schizophrenia log odds per standard deviation increase in the score (standard error) ³The two models evaluated were clumping and thresholding (C+T) or penalised regression (as implemented by the lassosum package)

726 727

725

728 Schizophrenia

In the SZ cohort, there were three network SZ PES which were significantly associated with 729 730 increased odds of SZ after multiple testing correction including networks for FES, GRIN2A, 731 and RPS17 (Table 2, Supplementary Figure 1a). In the GRIN2A network PES featuring 5037 732 variants constructed using penalised regression, explained approximately 0.35% of phenotypic variance on the liability scale (OR per SD in score = $1.19 [95\% \text{ CI: } 1.09, 1.29], P = 9.23 \times 10^{-10}$ 733 ⁴). We then conservatively adjusted for the best performing genome-wide SZ PRS and found 734 that the GRIN2A network PES remained significantly associated with SZ. In the FES and 735 RPS17 networks, their PES were just below the threshold for significance after PRS adjustment 736 737 (Supplementary Table 29). It is notable that the SZ network PES profiles were only marginally correlated with genome-wide SZ PRS (all r < 0.11, Supplementary Figure 2a), which suggests 738

⁷²³ 724

these scores may capture biologically aggregated risk which is distinct from the 739 740 undifferentiated genome-wide signal. Interestingly, the majority of individuals with SZ 741 (53.72%) had at least one elevated PES (for the disorder) in the highest decile, which was significant even after covariation for genome-wide PRS – OR = 1.45 [95% CI: 1.22, 1.67], P 742 743 = 1.57×10^{-3} . Interestingly, amongst individuals in this cohort with relatively low SZ PRS (lowest decile), 12 out of the 19 SZ cases had an elevated PES (63%), with a nominally 744 745 significant association remaining between elevated PES and SZ amongst those with low genome wide PRS (P = 0.027). Upon considering only SZ cases in terms of low PRS, we found 746 that 46.88% had at least one elevated PES. Taken together, these data suggest that some 747 748 individuals with otherwise low SZ PRS have localised genetic risk within these biological 749 networks. Given the relatively small number of SZ cases in the UKBB, we sought to replicate 750 our results using an independent case-control cohort from the ASRB ($N_{Cases} = 425$, $N_{Controls} =$ 251) rather than splitting the UKBB cohort into a training and validation set. The PES and PRS 751 models were retrained in the UKBB from the same GWAS with the ASRB cohort removed. 752 We were able to nominally replicate the association of the FES network PES with SZ in the 753 754 ASRB (OR per SD = 1.21 [95% CI: 1.04, 1.38], P = 0.024), whilst the observed association 755 between the GRIN2A and RPS17 network PES and SZ and in the UKBB was not replicated 756 (Supplementary Table 30).

757

758 *Bipolar disorder*

BIP PES within these networks was then profiled in the UKBB training set (Table 2, 759 760 Supplementary Figure 1b). Interestingly, there were more of the directional anchor gene network PES associated with BIP than SZ, which may have been a reflection the greater 761 762 statistical power afforded by the larger number of BIP cases in the UKBB. Specifically, all of the network BIP PES were significantly higher in cases, with the exception of the FADS1 763 764 network PES for which there was only a trend towards significance. Analogous to the SZ 765 cohort, the GRIN2A network PES explained the most phenotypic variance on the liability scale (0.39%), with each SD in the score associated with a 19% [95% CI: 12%, 26%] increase in the 766 767 odds of BIP. Moreover, adjustment for BIP genome wide PRS did not ablate the significance 768 of the *GRIN2A* network, *RPS17* network PES, and *FES* network PES, whilst the *PCCB* network PES trended towards significance (P = 0.1) after PRS covariation (Supplementary Table 31). 769 The correlations between each PES and BIP PRS were also small (Supplementary Figure 2b), 770 however, the *RPS17* network PES (r = 0.13), *CACNA1C* network PES (r = 0.14), and *PCCB* 771 772 network PES (r = 0.13) were slightly larger in terms of their PRS correlation than what was

773 observed for the SZ scores. We then investigated the characteristics of individuals with 774 elevated BIP PES and found like SZ that almost half of the BIP cases (49.1%) had at least one PES greater than or equal to the 90th percentile. There was also enrichment of BIP cases 775 amongst participants with an elevated PES after adjusting for BIP PRS (OR = 1.19 [95% CI: 776 777 1.04, 1.34], P = 0.027). Considering BIP cases in the lowest decile of the BIP PRS distribution, 36% of them had at least one top decile PES despite their low genome-wide burden, although 778 779 unlike SZ the association between elevated PES and case-status in this subcohort was not statistically significant. An independent BIP case-control cohort from the UKBB was utilised 780 781 to attempt to replicate these associations (Supplementary Table 32), and we found that the network RPS17 PES was significantly enriched in BIP cases in this validation cohort: whilst 782 783 there was a trend for the *GRIN2A* network PES (P = 0.052).

784

785 Sensitivity analyses for the GRIN2A network PES

The GRIN2A network PES explained the most phenotypic variance for SZ and BIP, and 786 survived covariation for genome-wide PRS – thus, we wanted to test whether constructing a 787 PES for this network with the GRIN2A gene excluded would still be associated. In other words, 788 789 we investigated whether there was an effect from variants mapped to the network without the 790 directional anchor gene itself. For example, the GRIN2A network PES with the GRIN2A gene removed, was still significantly enriched in both SZ and BIP ($P_{SZ} = 9.23 \times 10^{-4}$ and $P_{BIP} = 3.81$ 791 x 10⁻⁶). The relationship between genome-wide PRS and this PES was also examined in further 792 detail by constructing a 'residualised PES' whereby we obtained the normalised residuals from 793 794 a model that regressed SNP derived principal components, genotyping batch, and genome-795 wide PRS for BIP and SZ, respectively, on the GRIN2A network PES for either disorder. We 796 posit that the individuals with an elevated residualised PES are more likely to represent true enrichment in that network given that the effect of the genome wide PRS, along with variables 797 798 related to technical artefacts and population stratification, have been adjusted for. 799 Encouragingly, we find that the correlation between the raw GRIN2A network PES for either disorder and their respective residualised PES were highly concordant, with the majority of 800 individuals with an elevated *GRIN2A* PES (\geq 90th percentile) also in that same quantile for the 801 802 residualised PES (Figure 4a-b).

- 803
- 804
- 805
- 806

medRxiv preprint doi: https://doi.org/10.1101/2022.03.20.22272666; this version posted March 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.





It is made available under a CC-BY-NC 4.0 International license .

841 Figure 4. Schizophrenia and bipolar disorder GRIN2A directional anchor gene network pharmagenic enrichment scores and their relationship with PRS. The 842 843 scatter plots denote the concordance between the scaled unadjusted (raw) GRIN2A network PES for SZ (a) and BIP (b) and both a residualised score and genome wide 844 845 PRS. Specifically, the left-most scatterplots visualise the relationship between the raw GRIN2A network PES and the residuals from a model which regressed genotyping 846 847 batch, ten SNP derived principal components, and genome wide PRS for the disorder in question (Residualised GRIN2A PES). The dotted lines represent the 90th percentile 848 of the raw PES and residualised PES, respectively. The points coloured orange (SZ) 849 and red (BIP) indicate individuals with a PES in the 90th percentile or above for both 850 the raw and residualised scores. The right scatterplots plot the relationship between 851 852 genome wide PRS for SZ or BIP and the GRIN2A network PES. In these instances, the dotted vertical line denotes the 90th percentile of the *GRIN2A* PES, whilst the horizontal 853 dotted line denotes the 10th percentile of genome wide PRS. As a result, the points 854 855 coloured purple and blue in the SZ and BIP plots, respectively, are individuals with low 856 relative genome wide PRS (lowest decile) but high GRIN2A PES (highest decile).

857

858 Phenotypic correlations of directional anchor gene network scores support their 859 biological relevance

860 We then investigated the association of the directional anchor gene PES in an independent subset of the UKBB with other mental health phenotypes and systemic biochemical measures 861 862 (Supplementary Tables 33-35 Figure 5). The correlation profile of each PES relative to these phenotypes may also support its clinical utility, whilst it also provides an opportunity to further 863 864 establish what distinct properties these scores have from a genome wide PRS. Firstly, all SZ 865 and BIP network PES, along with their respective PRS, were regressed against 33 blood and 866 urine measures in up to 70,625 individuals, whilst oestradiol in females was also additionally 867 considered in a sex stratified analysis (Figure 5a). In both sexes, we found that the FADS1 network PES for SZ and BIP was significantly correlated with lipid related traits after 868 conservative Bonferroni correction for all PES/PES-trait pairs tested ($P < 1.11 \times 10^{-4}$). For 869 870 instance, these FADS1 network PES were negatively correlated with HDL cholesterol and 871 apolipoprotein A1 levels, whereas increase in the same PES was associated with higher measured triglycerides. The FADS1 network PES were also significantly associated other non-872 lipid biochemical traits including alkaline phosphatase, sex-hormone binding globulin 873 (SHBG), and urate. Notably, after adjusting PES for a genome-wide PRS for SZ or BIP, did 874

875 not ablate its association with the disorder, suggesting that these signals are not a product of 876 genome-wide polygenic inflation (Supplementary Tables 36-39). To the contrary, there was 877 evidence that PRS was correlated in the opposite direction with lipids to that of the corresponding PES. Given the strong lipid related signals, we also adjusted for statin use in an 878 879 additional sensitivity analysis, but this similarly did not markedly impact the findings (Supplementary Table 39). Using less stringent FDR correction (FDR < 0.05), revealed more 880 881 PES association with biochemical measures. This included a negative correlation between both the PCCB and FES network PES for SZ and insulin-like growth factor 1 (IGF1); as well as 882 883 positive correlation between RPS17 network PES for SZ and creatinine. However, there was 884 no direct effect of SZ or BIP PRS on IGF-1 or creatinine, with FES-related tyrosine kinase 885 activity previously shown in the literature to be associated with IGF-1 biology [47]. Sex 886 stratified analyses identified even more PES associated with a biochemical trait 887 (Supplementary Table 34) – for example, in males the SZ PCCB network PES was positively correlated with SHBG, which interestingly is in the opposite direction to the correlation of 888 SHBG observed with the FADS1 network PES, further highlighting biological heterogeneity 889 890 amongst different networks. The BIP CACNA1C network PES in males was also positively 891 correlated with direct bilirubin using an FDR cut-off, whilst the BIP GRIN2A network PES 892 was negatively correlated with measured total protein. Finally, we formally tested for evidence of sexual dimorphic effects of PES/PRS on each biochemical measure and revealed nominal 893 894 evidence of heterogeneity between sexes in these associations for some traits such as the effect of the CACNA1C network PES on direct bilirubin (Supplementary Table 40). 895

896

897

898

- 899
- 900
- 901
- 902
- 903 904

. - .

- 905
- 906
- 907
- 908

medRxiv preprint doi: https://doi.org/10.1101/2022.03.20.22272666; this version posted March 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted match 22, 2022. The copylight holder for this perpetuity. It is made available under a CC-BY-NC 4.0 International license .



Figure 5. Phenome-wide association studies (pheWAS) of each network PES or 943 PRS related to serum or urine biochemical measures and mental health disorders. 944 945 Heatmap of the association between each network PES and PRS with each trait tested for the biochemical measures (top) and self-reported mental health disorders (bottom). 946 947 Traits ordering derived from clustering by Pearson's distance. The variable visualised in the heatmaps for the continuous biochemical traits was the regression t value 948 949 (beta/SE), whilst for the binary mental health phenotypes it was the corresponding Zvalue from the logistic regression, whereby Z > 0 equates to an odds ratio for the 950 disorder > 0. Asterisks were utilised to denote the significance of the association - * =951 P < 0.05, ** = false discovery rate (FDR) > 0.05, and *** = family-wise error rate 952 953 (FWER) < 0.05.

954

We also performed a phenome-wide association study of each score with 14 self-reported 955 956 mental health disorders in the UKBB cohort, excluding SZ and BIP (Figure 5, Supplementary Table 35). The number of cases ranged from 66 for attention deficit/hyperactivity disorder 957 958 (ADHD) to 22,974 for depression, with the same cohort of 70,625 individuals without a self-959 reported mental health condition not featured in the SZ or BIP training/validation sets 960 leveraged as controls. Unsurprisingly, we found that SZ and BIP PRS were strongly associated 961 with increased odds of several mental health disorders after Bonferroni correction, but we also 962 found network PES associated with some of these phenotypes using FDR < 0.05 as the multiple-testing correction threshold. Specifically, there was an association between the SZ 963 964 CACNAIC PES and increased odds of depression, whilst the SZ RPS17 network PES was associated with increased odds of self-reported OCD. These disorders were also associated 965 966 with elevated SZ PRS, however, both PES remained significantly higher in those with the 967 respective self-reported phenotypes even after covariation for the effect of the SZ PRS. There 968 were also several other nominal associations (P < 0.05), including one of particular interest in 969 the case of the BIP FADS1 network PES, for which a higher score displayed some evidence of a protective effect on self-reported anorexia nervosa. Whilst this association does not survive 970 971 multiple testing correction, and thus should be interpreted cautiously, it is notable as the FADS1 972 network PES was associated with lipid profiles in an analogous direction to what has previously shown to be genetically correlated with anorexia nervosa GWAS via LD score regression [11, 973 974 21]. In summary, these data coupled with the biochemical associations support the distinct 975 nature of network PES from PRS and emphasise the unique insights that can be afforded by these partitioned scores. 976

977 DISCUSSION

In this study, we leverage genetics to identify novel drug repurposing candidates for psychotic disorders and show how they may be directed specifically to patients. This precision medicine approach is critical given that phenotypic and genetic heterogeneity confounds traditional interventions designed to target the entire disease population. We believe that a key advance in this study is that it provides a direct link between compounds with evidence for efficacy at the population level, a putative expression related mechanism, and genetic risk scores in the network of genes that interact with the prioritised drug target.

985

986 Transcriptomic and proteomic data integrated with GWAS through GReX (TWAS/PWAS) and 987 causal inference (MR) revealed six interesting target genes for SZ or BIP that could be 988 modulated in a risk decreasing direction by an approved drug. Compounds which target 989 *GRIN2A* in the risk decreasing direction, one of the genes prioritised for SZ, have previously been subjected to randomised control trials as an adjuvant to antipsychotic treatment. 990 Specifically, N-acetylcysteine and glycine intervention studies suggested that these compounds 991 992 could be effective in improving multiple symptom domains including negative and cognitive 993 related dimensions of the disorder [50, 51]. Omega-3 fatty acids, which are related to the 994 biology of the BIP candidate gene FADS1, have also been of interest in that disorder, although 995 trials have had contradictory results in terms of benefit [52]. This heterogeneity is unsurprising 996 given the complexity of the BIP phenotype and demonstrates the utility of an approach such as 997 ours which could more specifically target these interventions. The remaining genes and 998 respective repurposing candidates all had plausible biological links to neuronal biology or 999 psychiatric illness [53–56], and thus, warrant further investigation of their utility even without 1000 genetic stratification.

1001

1002 While these six candidates were supported by genetically regulated mRNA expression this was 1003 not confirmed by genetically regulated protein expression, however, this was probably due to reduced power to detect proteome related associations as this data is still relatively limited [48, 1004 1005 49] is still notably. There are also some limitations to using both the GReX and MR frameworks for target identification [7, 43, 46], although these are mitigated by a suite of sensitivity 1006 1007 analyses we performed, including probabilistic finemapping and colocalization, which strengthen our confidence in these six genes. Ideally, future statistical and molecular study of 1008 1009 these association signals should be undertaken to refine our understanding of the role of these genes in the pathophysiology of SZ and BIP. 1010

1011 We outlined a mechanism whereby genetic risk for the disorder could be profiled amongst the network of genes which were prioritised as repurposing opportunities and act as candidate 1012 1013 directional anchor genes based on their direction of effect (network PES). Crucially, we observed a notable portion of cases with low overall PRS but at least one elevated PES, further 1014 1015 supporting the biologically unique insights that may be gained from PES relative to an 1016 undifferentiated genome wide approach. Most of the scores also considered demonstrated at 1017 least nominal significance for association with either SZ or BIP, with PES like the GRIN2A 1018 network PES significantly enriched in both SZ and BIP even after conservatively correcting 1019 for the effect of a genome wide PRS. However, it should be noted that the training sets we used in this study were modestly powered, and larger training sets would be beneficial given that 1020 partitioned scores like PES will have smaller overall effect sizes than PRS. The relatively small 1021 trait-effect sizes of PES in terms of their phenotypic variance explained does not also 1022 necessarily preclude individual level relevance, particularly because PES like the FADS1 1023 1024 network PES displayed strong correlations with traits relevant to that network such as measured lipids. Penalised regression was also applied to the construction of these network PES rather 1025 1026 than just clumping and thresholding as was undertaken in previous PES studies [18–20]. These 1027 penalised regression PES did explain more variance in most of the networks considering the 1028 training set compared to clumping and thresholding, although selecting the appropriate constraint and tuning parameters when many combinations perform similarly is an ongoing 1029 1030 challenge for such approaches. For example, the best performing FES network PES for BIP was derived through penalised regression, however, it only included five variants, which is not 1031 1032 representative of the overall network. These issues highlight the need for future study in the construction of PES, particularly as popular genome wide approaches for PRS like LDpred and 1033 1034 SBayesR would need to be methodologically adapted for a local gene-set or network 1035 implemention [15]. The proportion of phenotypic variance explained by PES derived using 1036 these networks could also be boosted in future by incorporating rare and structural variation, 1037 as well as re-weighting effect sizes informed by functional annotation.

1038

While there is still work needed to confirm that the PES can effectively triage an individual's suitability for drug repurposing candidates in psychiatry and other disorders, this study represents a key methodological advance as it predicts the desired direction of effect needed to modulate a given target within the context of a PES. Previously, it was not clear whether agonism or antagonism of genes in the set would be clinically useful. Randomised placebo control trials of the PES approach would be a further step to demonstrate its utility and could

involve repurposed drugs stratified by the relevant PES or more complex study designs, suchas the multi-crossover "*N*-of-one" approach [57, 58]. In summary, we present a novel

- 1047 framework to inform precision drug repurposing in psychiatry that could account for individual
- 1048 level heterogeneity in genetic risk factors, and therefore, improve patient outcomes.
- 1049

1050 DATA AND CODE AVAILABILITY

1051 The analysis code for this study can be found in the following GitHub repository: 1052 https://github.com/Williamreay/Directional_anchor_gene_psyciatric_PES. Researchers can 1053 access the full UK Biobank data upon approval (https://www.ukbiobank.ac.uk/enable-your-1054 research/apply-for-access). The ASRB cohort is available upon reasonable request and ethics 1055 approval (https://www.neura.edu.au/discovery-portal/asrb/). The remaining data are all 1056 publicly available, as outlined in the studies cited at relevant positions throughout the main 1057 text.

1058

1059 ACKNOWLEDGEMENTS

1060 This work was supported by a National Health and Medical Research Council (NHMRC) grant 1061 (1188493). M.J.C. is supported by an NHMRC Senior Research Fellowship (1121474), URL: 1062 https://www.nhmrc.gov.au/. The funders had no role in study design, data collection and 1063 analysis, decision to publish, or preparation of the paper. W.R.R was supported by an 1064 Australian Government Research Training Program Stipend. This research was conducted 1065 using the UK Biobank resource under the application 58432.

- 1066
- 1067

1068 **DISCLOSURES**

1069 W.R.R and M.J.C have filed a patent related to the pharmagenic enrichment score approach –

1070 WIPO Patent Application: WO/2020/237314. The remaining authors declare no competing

1071 financial interests.

1072

1073 AUTHOR CONTRIBUTIONS

W.R.R. conceived and designed the study with input from M.J.C. W.R.R. performed the
primary analyses. M.P.G assisted with the quality control and processing of the UK Biobank
cohort. J.R.A performed the SNP imputation in the ASRB cohort. M.J.C, V.J.C, and M.J.G
contributed the ASRB cohort, as well as to critical interpretation of the results and drafting of
the manuscript.

1079

1080 REFERENCES

- 1081
- 1082 Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. 1. 1083 Acute and longer-term outcomes in depressed outpatients requiring one or several 1084 treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905–1917.
- 1085 2. Wimberley T, Støvring H, Sørensen HJ, Horsdal HT, MacCabe JH, Gasse C. Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. 1086 Lancet Psychiatry. 2016;3:358-366. 1087
- 1088 3. Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a 1089 European multicenter study. J Clin Psychiatry. 2007;68:1062–1070. 1090
- 1091 4. Hyman SE. Revolution stalled. Sci Transl Med. 2012;4:155cm11.
- 1092 5. Psychiatric drug discovery on the couch. Nat Rev Drug Discov. 2007;6:171–171.
- Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug 1093 6. 1094 repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 1095 2019;18:41-58.
- Reay WR, Cairns MJ. Advancing the use of genome-wide association studies for drug 1096 7. 1097 repurposing. Nat Rev Genet. 2021. 23 July 2021. https://doi.org/10.1038/s41576-021-00387-z. 1098
- Fava M. The promise and challenges of drug repurposing in psychiatry. World 1099 8. Psychiatry. 2018;17:28-29. 1100
- 1101 Schizophrenia Working Group of the Psychiatric Genomics Consortium, Ripke S. 9. Walters JT, O'Donovan MC. Mapping genomic loci prioritises genes and implicates 1102 synaptic biology in schizophrenia. Genetic and Genomic Medicine; 2020. 1103
- 1104 10. Stahl EA, Breen G, Forstner AJ, McQuillin A, Ripke S, Trubetskoy V, et al. Genomewide association study identifies 30 loci associated with bipolar disorder. Nat Genet. 1105 1106 2019;51:793-803.
- 1107 11. Watson HJ, Yilmaz Z, Thornton LM, Hübel C, Coleman JRI, Gaspar HA, et al. 1108 Genome-wide association study identifies eight risk loci and implicates metabopsychiatric origins for anorexia nervosa. Nat Genet. 2019;51:1207-1214. 1109
- 1110 12. Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, et al. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. 1111 Nat Genet. 2019;51:63-75. 1112
- 1113 13. Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic 1114 architecture of major depression. Nat Genet. 2018;50:668-681. 1115
- 1116 14. International Schizophrenia Consortium, Purcell SM, Wray NR, Stone JL, Visscher PM, 1117 O'Donovan MC, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460:748-752. 1118
- 1119 15. Ni G, Zeng J, Revez JA, Wang Y, Zheng Z, Ge T, et al. A Comparison of Ten 1120 Polygenic Score Methods for Psychiatric Disorders Applied Across Multiple Cohorts. Biological Psychiatry. 2021:S0006322321012634. 1121
- 16. Gaspar HA, Breen G. Drug enrichment and discovery from schizophrenia genome-wide 1122 1123 association results: an analysis and visualisation approach. Sci Rep. 2017;7:12460.
- Reay WR, Cairns MJ. The role of the retinoids in schizophrenia: genomic and clinical 1124 17. perspectives. Mol Psychiatry. 2020;25:706-718. 1125
- 18. Reay WR, Atkins JR, Carr VJ, Green MJ, Cairns MJ. Pharmacological enrichment of 1126 1127 polygenic risk for precision medicine in complex disorders. Sci Rep. 2020;10:879.

1128 19. Reay WR, El Shair SI, Geaghan MP, Riveros C, Holliday EG, McEvoy MA, et al. 1129 Genetic association and causal inference converge on hyperglycaemia as a modifiable factor to improve lung function. ELife. 2021;10:e63115. 1130 1131 20. Reay WR, Geaghan MP, 23andMe Research Team, Cairns MJ. Genome-wide metaanalysis of pneumonia suggests a role for mucin biology and provides novel drug 1132 repurposing opportunities. MedRxiv. 2021.01.24.21250424 DOI 1133 1134 10.1101/2021.01.24.21250424 1135 21. Reay WR, Kiltschewskij DJ, Geaghan MP, Atkins JR, Carr VJ, Green MJ, Cairns MJ. Genetic estimates of correlation and causality between blood-based biomarkers and 1136 1137 psychiatric disorders. Psychiatry and Clinical Psychology; 2021. 1138 22. Gusev A, Ko A, Shi H, Bhatia G, Chung W, Penninx BWJH, et al. Integrative 1139 approaches for large-scale transcriptome-wide association studies. Nat Genet. 1140 2016;48:245-252. 1141 23. Gandal MJ, Zhang P, Hadjimichael E, Walker RL, Chen C, Liu S, et al. Transcriptome-1142 wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. Science. 1143 2018;362. 1144 24. Wingo AP, Liu Y, Gerasimov ES, Gockley J, Logsdon BA, Duong DM, et al. Integrating human brain proteomes with genome-wide association data implicates new 1145 proteins in Alzheimer's disease pathogenesis. Nat Genet. 2021;53:143-146. 1146 25. Zhang J, Dutta D, Köttgen A, Tin A, Schlosser P, Grams ME, et al. Large Bi-Ethnic 1147 Study of Plasma Proteome Leads to Comprehensive Mapping of *cis* -pQTL and Models 1148 for Proteome-wide Association Studies. Genetics; 2021. 1149 1150 26. Mancuso N, Freund MK, Johnson R, Shi H, Kichaev G, Gusev A, et al. Probabilistic 1151 fine-mapping of transcriptome-wide association studies. Nat Genet. 2019;51:675–682. 27. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al. 1152 1153 Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 2014;10:e1004383. 1154 28. Zheng J, Haberland V, Baird D, Walker V, Havcock PC, Hurle MR, et al. Phenome-1155 1156 wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases. Nat Genet. 2020. 7 September 2020. https://doi.org/10.1038/s41588-1157 020-0682-6. 1158 29. de Klein N, Tsai EA, Vochteloo M, Baird D, Huang Y, Chen C-Y, et al. Brain 1159 expression quantitative trait locus and network analysis reveals downstream effects and 1160 putative drivers for brain-related diseases. Genomics; 2021. 1161 30. Robins C, Liu Y, Fan W, Duong DM, Meigs J, Harerimana NV, et al. Genetic control of 1162 1163 the human brain proteome. Am J Hum Genet. 2021;108:400–410. 31. 1164 Võsa U, Claringbould A, Westra H-J, Bonder MJ, Deelen P, Zeng B, et al. Unraveling the polygenic architecture of complex traits using blood eQTL metaanalysis. Genomics; 1165 1166 2018. 1167 32. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. ELife. 1168 1169 2018;7:e34408. 33. Freshour S, Kiwala S, Cotto KC, Coffman AC, McMichael JF, Song J, et al. Integration 1170 1171 of the Drug-Gene Interaction Database (DGIdb) with open crowdsource efforts. 1172 Bioinformatics; 2020. 34. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING 1173 v11: protein-protein association networks with increased coverage, supporting 1174 1175 functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607-D613. 1176

- 1177 35. Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, et al. g:Profiler: a web 1178 server for functional enrichment analysis and conversions of gene lists (2019 update). 1179 Nucleic Acids Research. 2019;47:W191-W198.
- 1180 36. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput Biol. 2015;11:e1004219. 1181
- Choi SW, O'Reilly PF. PRSice-2: Polygenic Risk Score software for biobank-scale 37. 1182 1183 data. GigaScience. 2019;8:giz082.
- 38. Mak TSH, Porsch RM, Choi SW, Zhou X, Sham PC. Polygenic scores via penalized 1184 regression on summary statistics. Genet Epidemiol. 2017;41:469-480. 1185
- 1186 39. Loughland C, Draganic D, McCabe K, Richards J, Nasir A, Allen J, et al. Australian Schizophrenia Research Bank: a database of comprehensive clinical, endophenotypic 1187 1188 and genetic data for aetiological studies of schizophrenia. Aust N Z J Psychiatry. 1189 2010;44:1029-1035.
- 40. Lee SH, Goddard ME, Wray NR, Visscher PM. A better coefficient of determination for 1190 genetic profile analysis. Genet Epidemiol. 2012;36:214-224. 1191
- 41. Aschard H, Vilhjálmsson BJ, Joshi AD, Price AL, Kraft P. Adjusting for heritable 1192 1193 covariates can bias effect estimates in genome-wide association studies. Am J Hum 1194 Genet. 2015;96:329-339.
- 42. Martin J, Khramtsova EA, Goleva SB, Blokland GAM, Traglia M, Walters RK, et al. 1195 1196 Examining Sex-Differentiated Genetic Effects Across Neuropsychiatric and Behavioral Traits. Biological Psychiatry. 2021;89:1127-1137. 1197
- Wainberg M, Sinnott-Armstrong N, Mancuso N, Barbeira AN, Knowles DA, Golan D, 1198 43. 1199 et al. Opportunities and challenges for transcriptome-wide association studies. Nat 1200 Genet. 2019;51:592-599.
- 44. Lipton SA, Choi Y-B, Takahashi H, Zhang D, Li W, Godzik A, et al. Cysteine 1201 1202 regulation of protein function--as exemplified by NMDA-receptor modulation. Trends 1203 Neurosci. 2002;25:474-480.
- 45. Yawalkar R, Changotra H, Gupta GL. Protective influences of N-acetylcysteine against 1204 1205 alcohol abstinence-induced depression by regulating biochemical and GRIN2A, 1206 GRIN2B gene expression of NMDA receptor signaling pathway in rats. Neurochem Int. 1207 2018;118:73-81.
- 46. Neumeyer S, Hemani G, Zeggini E. Strengthening Causal Inference for Complex 1208 Disease Using Molecular Quantitative Trait Loci. Trends in Molecular Medicine. 1209 2020;26:232-241. 1210
- 47. Stanicka J, Rieger L, O'Shea S, Cox O, Coleman M, O'Flanagan C, et al. FES-related 1211 1212 tyrosine kinase activates the insulin-like growth factor-1 receptor at sites of cell 1213 adhesion. Oncogene. 2018;37:3131-3150.
- 48. Gold L, Ayers D, Bertino J, Bock C, Bock A, Brody EN, et al. Aptamer-based 1214 1215 multiplexed proteomic technology for biomarker discovery. PLoS One. 2010;5:e15004.
- 1216 49. Rohloff JC, Gelinas AD, Jarvis TC, Ochsner UA, Schneider DJ, Gold L, et al. Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as 1217 Diagnostic and Therapeutic Agents. Mol Ther Nucleic Acids. 2014;3:e201. 1218
- 50. Javitt DC, Silipo G, Cienfuegos A, Shelley AM, Bark N, Park M, et al. Adjunctive high-1219 1220 dose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol. 1221 2001;4:385-391.
- 51. Yolland CO, Hanratty D, Neill E, Rossell SL, Berk M, Dean OM, et al. Meta-analysis of 1222 randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia. 1223 1224 Aust N Z J Psychiatry. 2020;54:453-466.

1225 52. Nasir M, Bloch MH. Trim the fat: the role of omega-3 fatty acids in psychopharmacology. Therapeutic Advances in Psychopharmacology. 1226

2019;9:204512531986979. 1227

- 1228 53. Moon AL, Haan N, Wilkinson LS, Thomas KL, Hall J. CACNA1C: Association With Psychiatric Disorders, Behavior, and Neurogenesis. Schizophrenia Bulletin. 1229 2018;44:958-965. 1230
- 1231 54. Okorji UP, Velagapudi R, El-Bakoush A, Fiebich BL, Olajide OA. Antimalarial Drug Artemether Inhibits Neuroinflammation in BV2 Microglia Through Nrf2-Dependent 1232 1233 Mechanisms. Mol Neurobiol. 2016;53:6426-6443.
- 1234 55. Chen W, Jin D, Shi Y, Zhang Y, Zhou H, Li G. The underlying mechanisms of lorlatinib penetration across the blood-brain barrier and the distribution characteristics 1235 of lorlatinib in the brain. Cancer Med. 2020;9:4350-4359. 1236
- Hjelm BE, Rollins B, Mamdani F, Lauterborn JC, Kirov G, Lynch G, et al. Evidence of 1237 56. Mitochondrial Dysfunction within the Complex Genetic Etiology of Schizophrenia. Mol 1238 1239 Neuropsychiatry. 2015;1:201-219.
- 57. Schork NJ. Personalized medicine: Time for one-person trials. Nature. 2015;520:609-1240 1241 611.
- Percha B, Baskerville EB, Johnson M, Dudley JT, Zimmerman N. Designing Robust N-1242 58.
- of-1 Studies for Precision Medicine: Simulation Study and Design Recommendations. J 1243 1244 Med Internet Res. 2019;21:e12641.

1245